Canadian drug user fees for product applications become effective Sept. 1.

This article was originally published in The Tan Sheet

28 Aug 1995
News

The Tan Sheet

Executive Summary

CANADIAN DRUG USER FEE SYSTEM WILL BE EFFECTIVE SEPT. 1 for premarket approval submission evaluations. Slated for publication in Part II of the Canada Gazette the week of Aug. 28, the "cost recovery" final regulation outlines fees that must be paid by prescription and nonprescription drug manufacturers for the review of drug-related submissions by the Canadian Health Protection Branch (HPB). The submissions evaluation fees are expected to bring in $25 mil. a year for HPB.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
Consumer
Subjects
OTC Drugs

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Consumer OTC Drugs

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS084223

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS084223

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Canadian drug user fees for product applications become effective Sept. 1.

News

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert